Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837051 | 0.85 | HPGD (0.49) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL6560408 | 0.82 | HPGD (0.49) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL3963337 | 0.76 | HPGD (0.60) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL2839532 | 0.76 | LOXL2 (0.64) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL17947424 | 0.75 | HPGD (0.64) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL485998 | 0.75 | HPGD (0.64) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL12085830 | 0.75 | HPGD (0.64) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL5536307 | 0.74 | HPGD (0.66) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL8275741 | 0.74 | HPGD (0.65) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL8069879 | 0.73 | ALOX5 (0.52) | HPGDCYP1A2CYP2C9CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-7667044-B2 | treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases | PROBIODRUG AG (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-1824846-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Probiodrug AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006058720-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060100253-A1 | Novel compounds for the treatment of neurological disorders | PROBIODRUG AG | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PREP, BACE1, BCHE | HPGD 672/4885CYP1A2 3336/4885CYP2C9 3428/4885 |
| US-20060100253-A1 | Novel compounds for the treatment of neurological disorders | PREP, BACE1, BCHE | HPGD 794/4885CYP1A2 3479/4885CYP2C9 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.